Probing the Assembly of HDL Mimetic, Drug Carrying Nanoparticles Using Intrinsic Fluorescence.
Sangram RautAshwini GarudBhavani NagarajanNirupama SabnisAlan T RemaleyRafal FudalaIgnacy GryczynskiZygmunt GryczynskiSergei V DzyubaJulian BorejdoAndras G LackoPublished in: The Journal of pharmacology and experimental therapeutics (2020)
Reconstituted high-density lipoprotein (HDL) containing apolipoprotein A-I (Apo A-I) mimics the structure and function of endogenous (human plasma) HDL due to its function and potential therapeutic utility in atherosclerosis, cancer, neurodegenerative diseases, and inflammatory diseases. Recently, a new class of HDL mimetics has emerged, involving peptides with amino acid sequences that simulate the the primary structure of the amphipathic alpha helices within the Apo A-I protein. The findings reported in this communication were obtained using a similar amphiphilic peptide (modified via conjugation of a myristic acid residue at the amino terminal aspartic acid) that self-assembles (by itself) into nanoparticles while retaining the key features of endogenous HDL. The studies presented here involve the macromolecular assembly of the myristic acid conjugated peptide (MYR-5A) into nanomicellar structures and its characterization via steady-state and time-resolved fluorescence spectroscopy. The structural differences between the free peptide (5A) and MYR-5A conjugate were also probed, using tryptophan fluorescence, Fӧrster resonance energy transfer (FRET), dynamic light scattering, and gel exclusion chromatography. To our knowledge, this is the first report of a lipoprotein assembly generated from a single ingredient and without a separate lipid component. The therapeutic utility of these nanoparticles (due to their capablity to incorporate a wide range of drugs into their core region for targeted delivery) was also investigated by probing the role of the scavenger receptor type B1 in this process. SIGNIFICANCE STATEMENT: Although lipoproteins have been considered as effective drug delivery agents, none of these nanoformulations has entered clinical trials to date. A major challenge to advancing lipoprotein-based formulations to the clinic has been the availability of a cost-effective protein or peptide constituent, needed for the assembly of the drug/lipoprotein nanocomplexes. This report of a robust, spontaneously assembling drug transport system from a single component could provide the template for a superior, targeted drug delivery strategy for therapeutics of cancer and other diseases (Counsell and Pohland, 1982).
Keyphrases
- energy transfer
- amino acid
- high density
- drug delivery
- quantum dots
- single molecule
- cancer therapy
- papillary thyroid
- clinical trial
- low density lipoprotein
- molecular dynamics simulations
- squamous cell
- primary care
- high resolution
- binding protein
- oxidative stress
- drug induced
- mass spectrometry
- squamous cell carcinoma
- protein protein
- lymph node metastasis
- high speed
- atomic force microscopy
- photodynamic therapy
- small molecule
- ms ms
- childhood cancer
- walled carbon nanotubes
- case control
- simultaneous determination
- tandem mass spectrometry
- monte carlo